Compare · LUNA vs MEDP
LUNA vs MEDP
Side-by-side comparison of Luna Innovations Incorporated (LUNA) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUNA and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $17.55B, about 81.0x LUNA ($216.7M).
- MEDP has been more active in the news (13 items in the past 4 weeks vs 1 for LUNA).
- MEDP has more recent analyst coverage (25 ratings vs 4 for LUNA).
- Company
- Luna Innovations Incorporated
- Medpace Holdings Inc.
- Price
- -
- -
- Market cap
- $216.7M
- $17.55B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2006
- 2016
- News (4w)
- 1
- 13
- Recent ratings
- 4
- 25
Luna Innovations Incorporated
Luna Innovations Incorporated develops, manufactures, and markets fiber optic test, measurement, and control products worldwide. It operates through two segments, Lightwave and Luna Labs. The Lightwave segment offers test and measurement products, which include optical vector analyzer, optical backscatter reflectometers, and the Phoenix family of tunable lasers; and Hyperion sensing solution that enable full-spectrum data acquisition and flexible peak detect algorithms of fiber-bragg grating (FBG), long period FBGs and fabry-perot sensors with low-latency access to data for closed loop feedback applications. This segment also provides polarization control products, including components, modules, and instruments to measure, manage, and control polarization and group delay in fiber optic networks; tunable lasers; Terametrix terahertz gauging and imaging products that provides precise single and multi-layer thickness, density, basis weight, and caliper thickness measurements; ODiSI sensing solution, which provides distributed strain and temperature measurements; and Hyperion sensing products that targets fiber optic sensing applications. The Luna Labs segment provides applied research for customers principally in the areas of sensing and materials, such as coatings, adhesives, composites, and bio-engineered materials. The company sells its products to telecommunications companies, defense agencies, government system integrators, researchers, original equipment manufacturers, distributors, testing labs, and strategic partners directly, as well as through manufacturer representative organizations, partner and distribution channels, technical sales engineers, value added resellers, and independent sales representatives. Luna Innovations Incorporated was incorporated in 1990 and is headquartered in Roanoke, Virginia.
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest LUNA
- TJC Completes Acquisition of Luna Innovations Incorporated
- Luna Innovations Enters into Definitive Agreement to be Acquired by TJC
- Luna Innovations Incorporated - Notice of Pendency and Proposed Settlement of Stockholder Derivative Action
- Luna Innovations Reports Q3 2025 Results Including Continued Bookings Growth and Margin Expansion
- Luna Announces Strong Start to 2025 with Substantial Bookings Growth
- Luna Innovations Announces Baker Tilly as New Independent Auditor
- Luna Innovations Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Luna Announces Updates on Operating Metrics and Intent to Deregister Stock
- SEC Form SCHEDULE 13G filed by Luna Innovations Incorporated
- Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
Latest MEDP
- SEC Form 4 filed by Medpace Holdings Inc.
- SEC Form 4 filed by Medpace Holdings Inc.
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.23% to 12,303 units (SEC Form 4)
- Director Kraft Robert O. converted options into 32 shares, increasing direct ownership by 3% to 987 units (SEC Form 4)
- Director Carley Brian T converted options into 36 shares, increasing direct ownership by 0.13% to 27,861 units (SEC Form 4)
- President & CEO Troendle August J. sold $30,320,929 worth of shares (48,667 units at $623.03), decreasing direct ownership by 13% to 338,225 units (SEC Form 4)
- UBS resumed coverage on Medpace with a new price target
- President & CEO Troendle August J. sold $1,589,941 worth of shares (2,564 units at $620.10), decreasing direct ownership by 0.66% to 386,892 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Medpace Holdings Inc.
- President & CEO Troendle August J. sold $27,403,895 worth of shares (43,916 units at $624.01), decreasing direct ownership by 10% to 389,456 units (SEC Form 4)